VendorMark said:One habit that pays for itself: post the method alongside the number.
That holds where the measurement is reliable. Where it is noisy — and a lot of what gets tracked here is noisy — the same reasoning produces confident nonsense.
Clinical perspective, offered as context rather than as advice. It is worth asking what the claim would look like if it were false. If nothing would look different, it is not a claim about the world and no amount of discussion will settle it.
Happy to go further on any of that.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsEndoResFellow said:It is worth asking what the claim would look like if it were false.
This matches mine closely enough to be worth saying so out loud. The detail I would add is minor and it is already implied above.
EndoResFellow said:It is worth asking what the claim would look like if it were false.
There is a second half to this that has not been said yet. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.
Worth separating that from the pharmacology, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.